Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
297.67B
Market cap297.67B
Price-Earnings ratio
21.12
Price-Earnings ratio21.12
Dividend yield
1.66%
Dividend yield1.66%
Average volume
6.88M
Average volume6.88M
High today
$70.00
High today$70.00
Low today
$67.64
Low today$67.64
Open price
$69.98
Open price$69.98
Volume
6.21M
Volume6.21M
52 Week high
$148.15
52 Week high$148.15
52 Week low
$66.88
52 Week low$66.88

NVO News

Quartz 7h
Here's how much Ozempic and similar drugs have soared in popularity since 2018

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging...

Quartz 1d
Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health. Both pharma giants unveiled...

TipRanks 2d
Novo Nordisk’s Market Leadership Bolstered by Strong Product Data and Promising Future Assets

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), with a price target of $105.00....

Analyst ratings

66%

of 35 ratings
Buy
65.7%
Hold
28.6%
Sell
5.7%

More NVO News

TipRanks 2d
Novo Nordisk presents results from STRIDE study on Ozempic

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabe...

TipRanks 4d
Novo Nordisk Stock Slips as Company Defends Weight Loss Drug Candidate

We know that the weight loss drug market has been downright explosive lately, but for drugmaker Novo Nordisk (NVO), it is starting to show signs of decline. The...

Benzinga 5d
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo...

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Quartz 5d
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup

Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has fi...

Quartz 5d
Wegovy sales took a hit this year. Novo's CEO blames off-brand competition

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment,...

TipRanks 5d
Novo Nordisk price target lowered to DKK 600 from DKK 700 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 600 from DKK 700 and keeps an Equal Weight rating on the...

TipRanks 5d
Novo Nordisk Stock Sees Its Largest Monthly Drop Since 2002

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest monthly loss since July 2002. Investors a...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.